Serum MIP-1beta and TNF-RII, but not CRP, were previously shown to be significantly decreased by infliximab treatment in sarcoidosis patients, with the decreases in these biomarkers correlating with the extent of clinical efficacy [15]. The gene discussed is TNF; the disease is sarcoidosis.